The key products in Bristol-Myers Squibb’s (BMY) oncology portfolio include Empliciti, Opdivo, Sprycel, and Yervoy. Let’s take a closer look at these drugs and their performances.
The above graph shows the revenues for BMY’s oncology drugs over the last few quarters.
Empliciti, a new oncology drug, was launched in the US markets in December 2015 and in the European markets in May 2016. The drug reported revenue of $55 million in 2Q17, a 62% rise compared to $34 million in 2Q16. The drug reported revenue of $37 million from US sales in 2Q17, a rise of 12% compared to 2Q16.
Opdivo is a human PD-1 blocking antibody used for the treatment of lung cancer and melanoma. Opdivo is part of BMY’s alliance with Ono Pharmaceutical. Opdivo reported a ~42% rise in revenue to $1.2 billion in 2Q17, compared to $840 million in 2Q16. The drug reported revenue of $768 million from US sales in 2Q17, a 19% rise compared to 2Q16.
Sprycel, an oral inhibitor, reported a rise of 12% in its 2Q17 revenue to $506 million, compared to $451 million in 2Q16, following increased demand for the drug in US markets. The drug reported revenue of $281 million from US sales during 2Q17, a 21% rise compared to 2Q16.
Yervoy, a monoclonal antibody used to treat melanoma, reported a 34% rise in its 2Q17 revenue to $322 million, compared to $241 million in 2Q16. Yervoy’s revenue saw a 37% rise in US markets, offset by a fall in international revenue due to competition. Yervoy competes with Merck & Co.’s (MRK) Keytruda.
To divest company-specific risks, investors can consider ETFs such as the PowerShares Dynamic Pharmaceuticals ETF (PJP), which holds 4.7% of its total assets in Bristol-Myers Squibb. PJP also holds 5.3% in Celgene (CELG), 4.7% in Pfizer (PFE), and 4.5% in Merck & Co.